ライフサイエンスコーパス: extragonadal

1 e patients with stage III and IV gonadal and extragonadal (all stages) MGCT were enrolled onto this P

2 rphic fashion, sex differences are caused by extragonadal and dosage effects of genes encoded on sex

3 d the responses of their spermatogenesis and extragonadal androgen actions (including gonadotropin su

4 ethod, that a specific T dose could maintain extragonadal androgen actions without simultaneously act

5 enesis, while simultaneously maintaining the extragonadal androgen actions, such as potency and libid

6 hibit gonadal testosterone production, block extragonadal androgen biosynthesis, or directly antagoni

7 Biosynthesis of extragonadal androgen may contribute to the progression

8 stration-resistant prostate cancers (CRPCs), extragonadal androgen sources may sustain tumor growth d

9 ptibility to degradation resulting in higher extragonadal androgen synthesis.

10 There were five extragonadal cases and two patients with late relapse (r

11 Among its extragonadal effects, follicle-stimulating hormone (FSH)

12 ersist in castrated rabbits, suggesting that extragonadal factors contribute to the differences in ve

13 varian or testicular function, while leaving extragonadal function intact.

14 entry criteria included relapsed gonadal and extragonadal germ cell cancer unlikely to be cured by st

15 The extragonadal germ cell tumors (EGCTs) represent a unique

16 Extragonadal germ cell tumors of infancy, one of the mos

17 iectomized WT than in ArKO, emphasizing that extragonadal local estradiol plays a critical role in fe

18 ration of primordial germ cells (PGCs) in an extragonadal location, followed by directed migration to

19 ed ovarian (n = 44), testicular (n = 7), and extragonadal (n = 22).

20 ctomy and before chemotherapy for those with extragonadal nonseminomas.

21 survival is not seen in those patients with extragonadal nonseminomatous germ cell tumors.

22 stage II-IV testicular, II-III ovarian, I-II extragonadal, or stage I gonadal tumors with subsequent

23 ting step for potent androgen synthesis from extragonadal precursors, thereby stimulating CRPC.

24 In contrast, for patients with an extragonadal primary tumor or with a testis primary tumo

25 ave a better prognosis than patients with an extragonadal primary tumor site or an IR to first-line t

26 Four of six patients with extragonadal primary tumors and two of four who failed t

27 Cases of gonadal and extragonadal primary were included in the nationwide coh

28 Two of three extragonadal seminomas are continuously disease-free.

29 GCTs) are neoplasms of the testis, ovary and extragonadal sites that occur in infants, children, adol

30 ic germ cell tumors (GCTs) commonly arise at extragonadal sites.

31 In considering the possibility of an extragonadal source of germ cells, we show expression of

32 These residual extragonadal sources of androgens allow prostate cancer

33 tem cells (hAd-PSCs) represent an attractive extragonadal stem cell source for regenerative therapies

34 he gonad, the FSHR has also been reported in extragonadal tissues including bone, placenta, endometri

35 confined to gonads and at low levels to some extragonadal tissues like human umbilical vein endotheli

36 in both male and female mammals in multiple extragonadal tissues.

37 None of the 32 patients with nonseminomatous extragonadal tumors are disease-free compared with 30 of

38 s age > 11 years with either stage III to IV extragonadal tumors or stage IV ovarian tumors with pred

39 n (n = 74) tumors and 165 with stage I to IV extragonadal tumors were enrolled.

40 % for patients with ovarian, testicular, and extragonadal tumors, respectively.

41 ts, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis,

42 g in infancy and early childhood are usually extragonadal, whereas older children predominantly prese